Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Feature Reviews in Biopharmaceuticals
share announcement

Feature Reviews in Biopharmaceuticals

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 15693

Special Issue Editors

Dr. Alfredo Berzal-Herranz

E-Mail Website
Guest Editor
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain
Interests: antiviral nucleic acids; therapeutic RNA; aptamers; RNA inhibitors; structure/function of RNA; RNA viruses
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Gill Diamond

E-Mail Website
Guest Editor
Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY 40292, USA
Interests: regulation of innate immunity; antimicrobial peptides; antifungal peptides; defensins; cathelicidins; novel antiviral compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The therapeutic applications of biomolecules, carbohydrates, peptides and nucleic acids have attracted much attention in recent decades. They have proven to be excellent candidates for the development of specific drugs to fight a wide variety of diseases. Advances have been achieved in the development of therapeutic strategies based on biomolecules, as well as strategies for the administration of biomolecules as drugs. This Special Issue aims to show, through high-quality review articles, the current state-of-the-art research of this interesting field. Therefore, we invite authors to contribute high-quality review articles covering all different aspects of the application and use of biomolecules as therapeutic drugs.

Dr. Alfredo Berzal-Herranz
Prof. Dr. Gill Diamond
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peptides
  • proteins
  • nucleic acids therapeutic RNAs
  • sugars

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

69 pages, 76143 KiB  
Review
Actinomycetes as Producers of Biologically Active Terpenoids: Current Trends and Patents
by Ekaterina V. Tarasova, Natalia A. Luchnikova, Victoria V. Grishko and Irina B. Ivshina
Pharmaceuticals 2023, 16(6), 872; https://doi.org/10.3390/ph16060872 - 12 Jun 2023
Cited by 2 | Viewed by 2006
Abstract
Terpenes and their derivatives (terpenoids and meroterpenoids, in particular) constitute the largest class of natural compounds, which have valuable biological activities and are promising therapeutic agents. The present review assesses the biosynthetic capabilities of actinomycetes to produce various terpene derivatives; reports the main [...] Read more.
Terpenes and their derivatives (terpenoids and meroterpenoids, in particular) constitute the largest class of natural compounds, which have valuable biological activities and are promising therapeutic agents. The present review assesses the biosynthetic capabilities of actinomycetes to produce various terpene derivatives; reports the main methodological approaches to searching for new terpenes and their derivatives; identifies the most active terpene producers among actinomycetes; and describes the chemical diversity and biological properties of the obtained compounds. Among terpene derivatives isolated from actinomycetes, compounds with pronounced antifungal, antiviral, antitumor, anti-inflammatory, and other effects were determined. Actinomycete-produced terpenoids and meroterpenoids with high antimicrobial activity are of interest as a source of novel antibiotics effective against drug-resistant pathogenic bacteria. Most of the discovered terpene derivatives are produced by the genus Streptomyces; however, recent publications have reported terpene biosynthesis by members of the genera Actinomadura, Allokutzneria, Amycolatopsis, Kitasatosporia, Micromonospora, Nocardiopsis, Salinispora, Verrucosispora, etc. It should be noted that the use of genetically modified actinomycetes is an effective tool for studying and regulating terpenes, as well as increasing productivity of terpene biosynthesis in comparison with native producers. The review includes research articles on terpene biosynthesis by Actinomycetes between 2000 and 2022, and a patent analysis in this area shows current trends and actual research directions in this field. Full article
(This article belongs to the Special Issue Feature Reviews in Biopharmaceuticals)
►▼ Show Figures

Graphical abstract

33 pages, 3554 KiB  
Review
Strategies for Improving Peptide Stability and Delivery
by Othman Al Musaimi, Lucia Lombardi, Daryl R. Williams and Fernando Albericio
Pharmaceuticals 2022, 15(10), 1283; https://doi.org/10.3390/ph15101283 - 19 Oct 2022
Cited by 28 | Viewed by 5560
Abstract
Peptides play an important role in many fields, including immunology, medical diagnostics, and drug discovery, due to their high specificity and positive safety profile. However, for their delivery as active pharmaceutical ingredients, delivery vectors, or diagnostic imaging molecules, they suffer from two serious [...] Read more.
Peptides play an important role in many fields, including immunology, medical diagnostics, and drug discovery, due to their high specificity and positive safety profile. However, for their delivery as active pharmaceutical ingredients, delivery vectors, or diagnostic imaging molecules, they suffer from two serious shortcomings: their poor metabolic stability and short half-life. Major research efforts are being invested to tackle those drawbacks, where structural modifications and novel delivery tactics have been developed to boost their ability to reach their targets as fully functional species. The benefit of selected technologies for enhancing the resistance of peptides against enzymatic degradation pathways and maximizing their therapeutic impact are also reviewed. Special note of cell-penetrating peptides as delivery vectors, as well as stapled modified peptides, which have demonstrated superior stability from their parent peptides, are reported. Full article
(This article belongs to the Special Issue Feature Reviews in Biopharmaceuticals)
►▼ Show Figures

Figure 1

Other

Jump to: Review

10 pages, 8240 KiB  
Opinion
2022 FDA TIDES (Peptides and Oligonucleotides) Harvest
by Othman Al Musaimi, Danah Al Shaer, Fernando Albericio and Beatriz G. de la Torre
Pharmaceuticals 2023, 16(3), 336; https://doi.org/10.3390/ph16030336 - 22 Feb 2023
Cited by 15 | Viewed by 7523
Abstract
A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out [...] Read more.
A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects. Full article
(This article belongs to the Special Issue Feature Reviews in Biopharmaceuticals)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop